Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

U Zangemeister-Wittke

Showing results (1-10 of 33) with videos related to

Pageof 4
Sort By:
Apoptosis : an International Journal on Programmed Cell Death|December 4, 2003
Bcl-2 antisense therapy for cancer: the art of persuading tumour cells to commit suicideU Zangemeister-Wittke, A Ziegler
Critical Reviews in Oncology/Hematology|June 6, 2006
Antisense molecules for targeted cancer therapyV Wacheck, U Zangemeister-Wittke
Biotherapy (Dordrecht, Netherlands)|January 1, 1991
Transfer of long-lasting tumor immunity by immune T cells from MHC congenic mice: migration, survival and tumor-protectivity of cytotoxic donor cellsU Zangemeister-Wittke, V Schirrmacher
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|August 22, 2001
Targeting tumor cell resistance to apoptosis induction with antisense oligonucleotides: progress and therapeutic potentialR A Olie, U Zangemeister-Wittke
Cellular and Molecular Life Sciences : CMLS|October 20, 1999
Novel approaches to the treatment of small-cell lung cancerU Zangemeister-Wittke, R A Stahel
Journal of Immunology (Baltimore, Md. : 1950)|July 1, 1989
Recruitment and activation of tumor-specific immune T cells in situ. CD8+ cells predominate the secondary response in sponge matrices and exert both delayed-type hypersensitivity-like and cytotoxic T lymphocyte activityU Zangemeister-Wittke, B Kyewski, V Schirrmacher
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2001
p53-Independent induction of apoptosis in human melanoma cells by a bcl-2/bcl-xL bispecific antisense oligonucleotideM Strasberg Rieber, U Zangemeister-Wittke, M Rieber
Cancer Immunology, Immunotherapy : CII|January 1, 1996
Preparation and functional evaluation of new doxorubicin immunoconjugates containing an acid-sensitive linker on small-cell lung cancer cellsB A Froesch, R A Stahel, U Zangemeister-Wittke
The Histochemical Journal|January 5, 1999
Epithelial glycoprotein-2 expression is subject to regulatory processes in epithelial-mesenchymal transitions during metastases: an investigation of human cancers transplanted into severe combined immunodeficient miceM Jojović, E Adam, U Zangemeister-Wittke, et al.
Acta Histochemica|November 1, 1996
Histochemistry of therapeutically relevant enzymes in human tumours transplanted into severe combined immunodeficient (SCID) mice: nitric oxide synthase-associated diaphorase, beta-D-glucuronidase and non-specific alkaline phosphataseU Schumacher, E Adam, U Zangemeister-Wittke, et al.
Pageof 4

Showing results (1-10 of 33) with videos related to

Sort By:
Pageof 4
Apoptosis : an International Journal on Programmed Cell Death|December 4, 2003
Bcl-2 antisense therapy for cancer: the art of persuading tumour cells to commit suicideU Zangemeister-Wittke, A Ziegler
Critical Reviews in Oncology/Hematology|June 6, 2006
Antisense molecules for targeted cancer therapyV Wacheck, U Zangemeister-Wittke
Biotherapy (Dordrecht, Netherlands)|January 1, 1991
Transfer of long-lasting tumor immunity by immune T cells from MHC congenic mice: migration, survival and tumor-protectivity of cytotoxic donor cellsU Zangemeister-Wittke, V Schirrmacher
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|August 22, 2001
Targeting tumor cell resistance to apoptosis induction with antisense oligonucleotides: progress and therapeutic potentialR A Olie, U Zangemeister-Wittke
Cellular and Molecular Life Sciences : CMLS|October 20, 1999
Novel approaches to the treatment of small-cell lung cancerU Zangemeister-Wittke, R A Stahel
Journal of Immunology (Baltimore, Md. : 1950)|July 1, 1989
Recruitment and activation of tumor-specific immune T cells in situ. CD8+ cells predominate the secondary response in sponge matrices and exert both delayed-type hypersensitivity-like and cytotoxic T lymphocyte activityU Zangemeister-Wittke, B Kyewski, V Schirrmacher
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2001
p53-Independent induction of apoptosis in human melanoma cells by a bcl-2/bcl-xL bispecific antisense oligonucleotideM Strasberg Rieber, U Zangemeister-Wittke, M Rieber
Cancer Immunology, Immunotherapy : CII|January 1, 1996
Preparation and functional evaluation of new doxorubicin immunoconjugates containing an acid-sensitive linker on small-cell lung cancer cellsB A Froesch, R A Stahel, U Zangemeister-Wittke
The Histochemical Journal|January 5, 1999
Epithelial glycoprotein-2 expression is subject to regulatory processes in epithelial-mesenchymal transitions during metastases: an investigation of human cancers transplanted into severe combined immunodeficient miceM Jojović, E Adam, U Zangemeister-Wittke, et al.
Acta Histochemica|November 1, 1996
Histochemistry of therapeutically relevant enzymes in human tumours transplanted into severe combined immunodeficient (SCID) mice: nitric oxide synthase-associated diaphorase, beta-D-glucuronidase and non-specific alkaline phosphataseU Schumacher, E Adam, U Zangemeister-Wittke, et al.
Pageof 4